1.European Heart Journal (2019) :doi:10.1093/eurheartj/ehz425.
2.Esmon CT. Targeting factor Xa and thrombin: impact on coagulation and beyond[J]. Thromb Haemost. 2014 Apr 1;111(4):625-33.
3.Angiolillo DJ, et al. Platelet thrombin receptor antagonism and atherothrombosis[J]. Eur Heart J 2010;31(1):17-28.
4.Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003; 41: Suppl S: 62S-69S.
5.Oldgren J, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial[J]. Eur Heart J. 2011 Nov;32(22):2781-9.
6.Alexander JH, et al. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome[J]. N Engl J Med 2011;365:699–708.
7.Mega JL, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome[J]. N Engl J Med. 2012 Jan 5;366(1):9-19.
8.Connolly SJ, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised,double-blind, placebo-controlled trial[J]. Lancet. 2017 Nov 10. http://dx./10.1016/S0140-6736(17)32458-3.
9.FDA Okays Rivaroxaban Plus Aspirin for Chronic CAD, PAD. Medscape. Oct 12, 2018. https://www./viewarticle/903344.